NPM1 and myelodysplastic syndrome: Applying the WHO 2022 classification 30 subjects with an NPM1 mutation were re-classified as AML, previously classified as MDS with excess blast type2 (MDS-EB2; n = 13), MDS with multi-lineage dysplasia (MDS-MLD; n = 9), MDS with excess blast type1 (MDS-EB1; n = 6) and MDS-U (n = 2) according to the WHO 2016 criteria.